arrow
M

Matteo Megna

university of naples federico ii
H指数:46
被引数:7,929

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world trajectories in psoriatic arthritis under risankizumab therapy

鲁安沙利单抗治疗下银屑病关节炎患者的真实世界轨迹

2026-09-230
PRE
Patient-Level Cumulative Clinical Benefit of Brodalumab Over 52 Weeks: A Multicentre Real-World Study-IL PSO (Italian Landscape Psoriasis)

52周内布达拉木单抗在患者层面的累积临床获益:一项多中心真实世界研究-IL PSO(意大利银屑病全景)

2026-09-170
OAAI
Early and Maintained Treat-to-Target Response with Ixekizumab up to 5 Years in Moderate-to-Severe Psoriasis: Analysis of the UNCOVER-3 Study

中重度银屑病患者经伊克珠单抗治疗5年实现早期并维持至目标应答:UNCOVER-3研究分析

2026-09-160
PRE
Real-World Effectiveness and Safety of Bimekizumab for Moderate-to-Severe Hidradenitis Suppurativa: A Multicenter Retrospective Study from the Italian Landscape HS (IL-HS)

贝美克单抗治疗中度至重度化脓性汗腺炎的真实世界有效性与安全性:一项来自意大利化脓性汗腺炎景观(IL-HS)的多中心回顾性研究

2026-08-280
OAAI
Treatment-associated phenotype switching between psoriasis and atopic dermatitis

银屑病和特应性皮炎治疗相关的表型转换

2026-05-140
PRE
Long-Term Outcomes of Secukinumab in Moderate-to-Severe Hidradenitis Suppurativa: A Multicentre Cohort Study

中重度 Hidradenitis suppurativa 患者 Secukinumab 的长期疗效:一项多中心队列研究

2026-03-170
PRE
Short-Term Effectiveness and Safety of Deucravacitinib in Psoriasis: A Multicenter Real-World Study with Scalp-Specific Outcomes—IL PSO (Italian Landscape Psoriasis)

德卡巴替尼在银屑病中的短期有效性与安全性:一项多中心真实世界研究,重点关注头皮特定结局——IL PSO(意大利银屑病全景研究)

2026-03-160
OAAI
The impact of apremilast on cardiometabolic and inflammation indexes in psoriatic patients at high cardiovascular risk: A real-world multicenter retrospective observational study

阿普米ласт对心血管高风险银屑病患者的代谢和炎症指标的影响:一项真实世界多中心回顾性观察性研究

2025-12-100
PRE
Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective Study

银屑病患者中 guselkumab 的长期真实世界有效性与药物生存率:一项为期5年的回顾性研究

2025-09-160
OA